Alzheimer ‘s
FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting
FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.
Biogen Expands Leqembi Field Force and Launches Omnichannel Campaigns for Next Phase
Biogen, Leqembi, field force, expansion, omnichannel campaigns, launch phase, Alzheimer’s treatment